Fidia Farmaceutici, SpA
http://www.fidiapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fidia Farmaceutici, SpA
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.
Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Bioos
- Fidia Pharma Group
- Glaucoom
- OftaH.T. e Neoox
- Soluciones Bioregenerativas SL
- Sooft Italia
- Fidia Pharma Austria GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice